Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
FDA rejects Replimune’s oncolytic virus
There are questions about vuso-vec’s supporting and confirmatory trials.
Columvi avoids its worst-case scenario
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
Adcom puts up a Blenrep roadblock
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
The FDA's "radical transparency", up to a point
A newly published cache of CRLs includes six novel oncology drugs.
More problems for BioNTech & Roche’s neoantigen shot
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Dizal's US first; now what?
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
